Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2000-09-14
2003-11-18
Allen, Marianne P. (Department: 1631)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S558000, C424S562000, C424S570000, C424S582000
Reexamination Certificate
active
06649160
ABSTRACT:
TECHNICAL FIELD
The present invention relates to methods of transplanting cells to create a localized immunosuppressive and trophic effect in tissue.
BACKGROUND OF THE INVENTION
Transplantation of cells and tissues is being utilized therapeutically in a wide range of disorders including but not limited to from cystic fibrosis (lungs), kidney failure, degenerative heart diseases to neurodegenerative disorders.
As an example, the central nervous system (CNS) (brain and spinal cord) has poor regenerative capacity which is exemplified in a number of neurodegenerative disorders. An example of such a disorder is Parkinson's disease. The preferred pharmacotherapy for Parkinson's disease is L-dopa which helps the symptoms of this disease in humans. However, the neuropathological damage and the debilitating progression is not reversed by this treatment protocol.
Laboratory and clinical studies have shown the transplantation of cells into the CNS is a potentially significant alternative therapeutic modality for neurodegenerative disorders such as Parkinson's disease (Wictorin et al., 1990; Lindvall et al., 1990; Sanberg et al., 1994; Bjorklund and Stenevi, 1985; Freeman et al., 1994). In some cases, transplanted neural tissue can survive and form connections with the CNS of the recipient (i.e. the host) (Wictorin et al., 1990). When successfully accepted by the host, the transplanted tissue,(i.e. the graft) has been shown to ameliorate the behavioral deficits associated with the disorder (Sanberg et al., 1994). The obligatory step for the success of this kind of treatment is the prevention of graft rejection (i.e. graft acceptance).
Currently, fetal neural tissue is the primary graft source for neural transplantation (Lindvall et al., 1990; Bjorklund, 1992; Isacson et al., 1986; Sanberg et al., 1994). Other viable graft sources include adrenal chromaffin cells and various cell types that secrete neural growth factors and trophic factors. The field of neural tissue transplantation as a productive treatment protocol for neurodegenerative disorders has received much attention resulting in its progression to clinical trials. Preliminary results and clinical observations are promising although the graft rejection phenomenon remains a problem.
Recently, studies have suggested that Sertoli cells, when simultaneously transplanted with pancreatic islet cell into the diabetic rat, act as an effective local immunosuppressant on the host tissue (Selawry and Cameron, 1993). As a result, the graft is not rejected and the islets remain viable allowing the transplanted &bgr;-cells to function normally and produce insulin for an indefinite period of time. As a result, the accepted graft overcomes the primary physiological dysfunction of hyperglycemia thereby alleviating the related complications of this endocrine disorder. This cell transplantation protocol is accomplished without prolonged systemic immunosuppression, otherwise necessary when islets are transplanted without Sertoli cells.
In general, systemic immunosuppression is necessary if successful transplantation is to be achieved in humans. Immunosuppression of the entire body (i.e. systemic) can result, eventually, in graft acceptance. It is acquired, however, by placing the individual at medical risk making the immunosuppressant therapy itself more of a liability than a benefit in some cases. For a lack of a better immunosuppressant treatment, systemic immunosuppressants, with Cyclosporine-A (CsA) as the treatment choice, have been used as adjunctive therapy in neural and other transplantation protocols (Sanberg et al., 1994; Freeman et al., 1994; Borlongan et al., 1995). Arguably, systemic CsA treatment may be contraproductive to successful graft acceptance in the CNS because of its systemic effect and because CsA itself has been shown to cause detrimental side effects and may, in fact, be cytotoxic to neural tissues (Berden et al., 1985; de Groen et al., 1984).
It would be desirable to enhance the productive cell transplantation techniques already utilized for neurodegenerative disorders, such as Parkinson's disease, in ways which would more effectively slow the neurodegenerative disease process, more actively promote the re-establishment of normal neural tissue physiology and better alleviate the functional disabilities associated with the neural tissue dysfunction. Likewise, it would be desirable to avoid systemic immunosuppression with the ability to locally immunosuppress (i.e. at the graft site) by an immunosuppressant which is biologically tolerated by the host. Sertoli cells may provide this desired option since it is clear from the diabetic studies, as summarized above, that co-transplantation with Sertoli cells will deliver local immunosuppression and promote, therefore, efficient graft acceptance and functional restoration of the tissue-related dysfunction.
SUMMARY OF THE INVENTION AND ADVANTAGES
In accordance with the present invention, there is provided a method of producing a sustained localized immunosuppressive effect and trophic effect in tissue by transplanting Sertoli cells proximate to the tissue.
REFERENCES:
patent: 4829000 (1989-05-01), Kleinman et al.
patent: 5702700 (1997-12-01), Sanberg et al.
patent: 5725854 (1998-03-01), Selawry
patent: 5759534 (1998-06-01), Selawry
patent: 5827736 (1998-10-01), Heller et al.
patent: 5830460 (1998-11-01), Sanberg et al.
patent: 5834001 (1998-11-01), Dionne et al.
patent: 5843430 (1998-12-01), Selawry
patent: 5849285 (1998-12-01), Selawry
patent: 5858354 (1999-01-01), Brinster
patent: 5869077 (1999-02-01), Dionne et al.
patent: 5871767 (1999-02-01), Dionne et al.
patent: 5874099 (1999-02-01), Dionne et al.
patent: 5942437 (1999-08-01), Sanberg et al.
patent: 5958404 (1999-09-01), Selawry
patent: 6001643 (1999-12-01), Spaulding
patent: 6036951 (2000-03-01), Sanberg et al.
patent: 6037175 (2000-03-01), Cameron et al.
patent: 6083523 (2000-07-01), Dionne et al.
patent: 6149907 (2000-11-01), Selawry
patent: 6322804 (2001-11-01), Dionne et al.
patent: 2002/0065212 (2002-05-01), Selawry et al.
patent: 2002/0150603 (2002-10-01), Dionne et al.
patent: WO 92/06702 (1992-04-01), None
patent: WO 95/28167 (1995-10-01), None
patent: WO 96/28030 (1996-09-01), None
patent: WO 96/28174 (1996-09-01), None
patent: WO 96/33264 (1996-10-01), None
patent: WO 96/40178 (1996-12-01), None
patent: WO 97/33470 (1997-09-01), None
patent: WO 01/66698 (2001-09-01), None
patent: WO 02/063938 (2002-08-01), None
Koutouzis et al.,“Cell Transplantation for Central Nervous System Disorders”, Critical Reviews in Neurobiology, (1994) vol. 8 No. 3 pp 125-162.*
Bellgrau, D. et al., “A role for CD95 ligand in preventing graft rejection”Nature, Oct. 19, 1995, 377:630-632.
Berden et al. “Severe central nervous system toxicity associated with cyclosporine”Lancet1985, 26:219-220.
Bjorklund and Stenevi “Intracerebral neural grafting: a historical perspective” in Bjorklund, A. and U. Stenevi, eds.Neural grafting in the mammalian CNS, Amsterdam: Elsevier 1985, 3-11.
Bjorklund “Dopaminergic transplants in experimental Parkinsonism: cellular mechanisms of graft-induced functional recovery”Current Opinion in Neurobiology1992, 2:683-689.
Borlongan et al“Cyclosporine-A increases spontaneous and dopamine agonist-induced locomotor behavior in normal rats”Cell Transplant1995, 4:65-73.
Byers, S. et al. “Sertoli Cell Junctions and the Seminiferous Epithelium Barrier”, pp. 431-446, inThe Sertoli Cell, L.D. Russell and M.D. Griswold, Eds, Cache River Press, 1993.
Cameron, D.F. et al. “Formation of Sertoli Cell-Enriched Tissue Constructs Utilizing Simulated Microgravity Technology”Annals New York Acad. Sci., Nov. 2001, 944:420-428.
Cameron, D.F. et al. “Formation of Insulin-Secreting, Sertoli-Enriched Tissue Constructs by Microgravity Coculture of Isolated Pig Islets and Rat Sertoli Cells”In Vitro Cell. Dev. Biol.-Animal, Sep. 2001, 37:490-498.
Cameron, D.F. et al. “Longterm Microgravity Coculture of Sertoli Cells and Islets Enhances Insulin Secretion”Endocrin. Proc., Jun. 15, 1999, P2-230, abstract.
Cameron, D.F. and K.
Borlongan Cesario V.
Cameron Don F.
Sanberg Paul R.
Allen Marianne P.
Saliwanchik Lloyd & Saliwanchik
University of South Florida
LandOfFree
Sertoli cells as transplantation facilitator for cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sertoli cells as transplantation facilitator for cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sertoli cells as transplantation facilitator for cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3130468